HOME >> MEDICINE >> NEWS
Combination therapy does not appear to benefit cardiac patients before heart catheter procedure

Patients with acute myocardial infarction (MI - heart attack) who are referred for percutaneous coronary intervention (such as angioplasty and stent placement in the coronary artery) do not have a reduction in the amount of damaged heart tissue when administered two drugs compared with a single drug to restore blood flow, according to a study in the February 25 issue of The Journal of the American Medical Association (JAMA).

According to background information in the article, "In hospitals with catheterization facilities, primary percutaneous coronary interventions (PCIs) are better then thrombolysis (drug therapy used to dissolve blood clots) in patients with ST-segment elevation acute MI. Specifically designed randomized trials have also shown that patients with acute MI presenting at hospitals without catheterization facilities benefit more from PCI performed after transfer to centers with catheterization laboratories than from on-site thombolysis."

Adnan Kastrati, M.D., from Deutsches Hezzentrum, Technische Universitat, Munich, Germany, and colleagues from the Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators, assessed whether early administration of the combination of the drugs reteplase plus abciximab produces better reduction of infarct size compared with abciximab alone in patients with acute MI referred for PCI. The study, conducted from May 3, 2001 through June 2, 2003, included 253 patients who were admitted to 13 community hospitals without catheterization facilities (n=186) and to 5 hospitals with catheterization facilities (n=67), within 12 hours of symptoms of an acute MI. Patients randomly received either the combination of reteplase and abciximab (n=125) or abciximab (n=128) alone. All patients were then transferred for PCI. Infarct size was later determined by imaging from a single-photon emission computed tomography (SPECT).

"The final infarct size of the left ventricle, the primary en
'"/>

Contact: Adnan Kastrati, M.D.
kastrati@dhm.mhn.de
JAMA and Archives Journals
24-Feb-2004


Page: 1 2

Related medicine news :

1. Combination treatment helps thyroid cancer patients live longer
2. Combination therapy, not medication alone, most effective for treating children with OCD
3. Combination of erection pill and testosterone gel may benefit men who fail treatment with pill alone
4. Combination therapy w/ ACTOS (pioglitazone HCI) shown to improve components of diabetic dyslipidemia
5. Combination PET/CT should be used to determine stage of non-small cell lung cancer
6. Combination of toxin and poison may be novel treatment for leukemia
7. Combination drug therapy could substantially improve symptoms of rheumatoid arthritis
8. Combination drug therapy offers hope for malaria treatment
9. Combination therapy significantly delays progression of benign prostatic hyperplasia
10. Combination, order of anti-HIV drugs make a difference in first-time recipients
11. Combination of HIV/malaria increases complications during pregnancy

Post Your Comments:
(Date:9/4/2015)... ... September 04, 2015 , ... Mike Day, a former Navy SEAL ... in the Ironman World Championships in Kona on October 10th. , Mike is running ... Injury (TBI) through combat and the cutting-edge treatments that restore their quality of life. ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... The USC ... was ranked number 9 nationwide by Doximity. Faculty, residents and staff are honored ... great pride in the quality of our ophthalmology residency program. Our faculty places a ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... and development of its first neighborhood created specifically for adults with intellectual, developmental ... the Phoenix Metro area and feature 30 cottage or “pocket” homes. In this ...
(Date:9/4/2015)... DC (PRWEB) , ... September 04, 2015 , ... ... they all pale in comparison to settlements under the Stark physician self-referral law. ... an upcoming Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will detail ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... company today announced that it has entered into a multi-year agreement with Health ... agreement to bridge the link between American healthcare, Jamaican healthcare and Health City ...
Breaking Medicine News(10 mins):Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6
(Date:9/4/2015)... , Sep. 04, 2015 ... the addition of the "Stability Testing of Pharmaceuticals ... their offering. By attending this comprehensive two ... to design efficient stability studies that are suitable for ... appropriate stability studies and manage stability samples and facilities ...
(Date:9/4/2015)... , September 4, 2015 ... today announces that Hutchison MediPharma Limited ("HMP"), its ... in the second proof-of-concept ("POC") trial of fruquintinib ... cancer ("NSCLC") in China . ... succeeded in meeting the primary efficacy endpoint of ...
(Date:9/3/2015)... , Sept. 3, 2015 Report ... market? Which areas are going to grow at the ... revenues to 2025, assessing data, trends, opportunities and prospects ... charts, and graphs. Discover the most lucrative areas in ... study lets you assess forecasted sales at overall world ...
Breaking Medicine Technology:Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4
Cached News: